Form 4: Inovio Pharmaceuticals Director David B. Weiner Reports Stock Transaction

Director David B. Weiner reports the vesting and acquisition of 2,166 shares of Inovio Pharmaceuticals common stock on May 15, 2024, related to restricted stock units.

Summary

• On May 15, 2024, David B. Weiner, a director of Inovio Pharmaceuticals, acquired 2,166 shares of common stock.
• This acquisition resulted from the vesting of restricted stock units.
• Following the transaction, Weiner directly owns 82,509 shares of Inovio Pharmaceuticals.
• The restricted stock units vested 100% on May 15, 2024.
• The filing gives effect to a 1-for-12 reverse stock split that Inovio Pharmaceuticals implemented on January 24, 2024.

Sentiment

Score: 5

Explanation: This is a neutral reporting of a stock transaction by a company director. It doesn't inherently indicate positive or negative sentiment, but rather provides factual information.

Positives

• The vesting of restricted stock units indicates that performance milestones or time-based vesting requirements have been met.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates the vesting of previously granted equity compensation.

Stakeholder Impact

• The transaction may have a minor impact on shareholders due to the change in ownership by a company director.

Key Dates